Colin Murdoch

President

Isomorphic Labs

Artificial Intelligence

Healthcare & Wellness

About Me

Colin Murdoch is President of Isomorphic Labs, a company with a mission to advance human health through AI-first drug design; and Chief Business Officer of Google DeepMind, a world-leading AI research lab. Colin is an influential business leader with a distinctive skill in building and leading high-performance teams to unleash the full potential of cutting-edge AI and other technologies. He has decades of experience, from pioneering start-ups and industry-leading global companies, to developing and running technology-based businesses. Instrumental in founding Isomorphic Labs, Colin is also the company’s first President, leading a world-class team responsible for all aspects of the business, including AI research, drug design, business development, and operations. Colin has an enduring passion for the ability of technology to help solve some of society’s biggest challenges.

Hear My Insights

AI Drug Discovery

As AI systems grow more capable in modeling complex biological systems, drug discovery is entering a new era — one where machine learning models don't just assist researchers, but actively generate hypotheses, design molecules, and predict therapeutic outcomes. This session explores the shift from traditional trial-and-error approaches to AI-driven methodologies that can integrate biological data at unprecedented scale and speed. What does it mean to have AI as a true collaborator in science? Can these systems unlock treatments for diseases that have eluded medicine for decades? As AI takes on a greater role in healthcare decision-making, how do we ensure that its use remains transparent, equitable, and ethically sound?

From Lab to Market: AI-Powered Drug Discovery in Action

Colin Murdoch, President of Isomorphic Labs and CBO at Google DeepMind, reveals the blueprint for translating AI's potential into biotech reality. In this exclusive session, he unpacks Isomorphic Labs' journey, showing how the company has bridged the gap between complex algorithms, life-changing drug discovery – and a market-ready business.